Post by National Cancer Centre Singapore

An effective new treatment for triple-negative breast cancer has emerged! 💥 🎉 Congrats to 𝗣𝗿𝗼𝗳 Rebecca Dent, 𝗗𝗲𝗽𝘂𝘁𝘆 𝗖𝗘𝗢 (𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹), 𝗡𝗖𝗖𝗦, and lead author of a recently published Annals of Oncology study demonstrating positive findings from a Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) to treat aggressive and previously untreated triple-negative breast cancer (TNBC). ❓𝗪𝗵𝘆 𝗮𝗿𝗲 𝗻𝗲𝘄 𝗧𝗡𝗕𝗖 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗻𝗲𝗲𝗱𝗲𝗱? TNBC patients with previously untreated and advanced disease have poor prognosis and limited treatment options, especially when they are not candidates for immunotherapy. The TROPION-Breast02 trial, an open-label phase III trial, tested whether the antibody drug conjugate (ADC) Dato-DXd improves survival for this group of patients. In a study of 644 patients randomised to receive either the ADC or chemotherapy, Dato-DXd demonstrated significantly improved progression-free survival (10.8 vs 5.6 months) and overall survival (23.7 vs 18.7 months). 🫶 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀: TNBC is an aggressive and devastating disease that hits women in the prime of their lives and new treatments give hope to patients and their families. The results of this clinical trial indicate a potential new breakthrough that improves treatment for TNBC. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗵𝗲𝗿𝗲: https://lnkd.in/d9XnFY4N #NCCSResearch #CancerResearch #ClinicalTrials #TripleNegativeBreastCancer #BreastCancerResearch